Gut microbiota, innate immune pathways, and inflammatory control mechanisms in patients with major depressive

Javier R Caso1,2, Karina S MacDowell1,2, Ana González-Pinto3

  • 1Department of Pharmacology & Toxicology, Faculty of Medicine, Universidad Complutense de Madrid (UCM), Madrid, Spain.

Translational Psychiatry
|December 22, 2021
PubMed

Insights

Major depressive disorder (MDD) is linked to gut bacteria changes, with specific genera like Dialister depleted in patients. These microbial shifts, particularly in active MDD, may influence depression pathophysiology and immune responses.

Area of Science:

  • Microbiome research
  • Neuroscience
  • Immunology

Background:

  • Alterations in gut microbiota are implicated in major depressive disorder (MDD) pathophysiology.
  • The direct relationship between gut microbiota and MDD remains unclear, particularly concerning immune system involvement.

Purpose of the Study:

  • To investigate the specific patterns of gut microbiota and their association with major depressive disorder (MDD).
  • To explore the link between microbial alterations, immune markers, and the severity of depressive symptoms.

Main Methods:

  • Recruited male and female patients with active MDD (a-MDD), in remission/mild MDD (r-MDD), and healthy controls (HC).
  • Assessed psychopathological states and collected fecal and blood samples for analysis.
  • Quantified inducible nitric oxide synthase, oxidative stress, lipopolysaccharide, and bacterial genus abundance.

Main Results:

  • MDD patients showed higher inducible nitric oxide synthase expression and oxidative stress compared to HC.
  • Lipopolysaccharide levels were elevated in a-MDD patients, suggesting bacterial translocation.
  • Specific bacterial genera (Bilophila, Alistipes) were increased, while others (Anaerostipes, Dialister) were decreased in MDD patients, with Dialister notably depleted in a-MDD.

Conclusions:

  • Gut microbiota composition and immune pathways are altered in MDD patients.
  • The most significant microbial changes were observed in patients with active MDD, correlating with clinical severity.
  • These findings suggest a role for gut microbial dysbiosis in the pathophysiology of depression.

Related Concept Videos

Depressive Disorders: Etiology01:27

Depressive Disorders: Etiology

Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
181
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
537
Depression: Overview01:18

Depression: Overview

Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
417
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
412
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
560
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
230